Ontology highlight
ABSTRACT:
SUBMITTER: Chou S
PROVIDER: S-EPMC6097806 | biostudies-literature | 2018 Sep
REPOSITORIES: biostudies-literature
Chou Sunwen S Ercolani Ronald J RJ Derakhchan Katayoun K
Antiviral research 20180721
The human cytomegalovirus (CMV) UL97 kinase inhibitor maribavir is in Phase III clinical trials as antiviral therapy, including use for infections refractory or resistant to standard therapy. To assess its activity in combination with approved and experimental CMV antivirals, and with the mTor inhibitor rapamycin (sirolimus), drug effects were tested by in vitro checkerboard assays and the data were analyzed using a three dimensional model based on an independent effects definition of additive i ...[more]